Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2
Xingui Liu, Alexia F. Kalogeropulou, Sofia Domingos, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 37, pp. 16930-16952
Open Access | Times Cited: 104

Showing 26-50 of 104 citing articles:

Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 12
Structural and Physicochemical Features of Oral PROTACs
Markus Schade, James S. Scott, Thomas G. Hayhow, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 13106-13116
Closed Access | Times Cited: 12
The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation
Tomasz Sobierajski, Joanna Małolepsza, Marta Pichlak, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104032-104032
Open Access | Times Cited: 9
Research progress of PROTACs for neurodegenerative diseases therapy
Zhifang Cai, Zunhua Yang, Huilan Li, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107386-107386
Closed Access | Times Cited: 8
Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases
Hossein Mousavi, Mehdi Rimaz, Behzad Zeynizadeh
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 9, pp. 1828-1881
Closed Access | Times Cited: 8
Relocalizing transcriptional kinases to activate apoptosis
Roman C. Sarott, Sai Gourisankar, Basel A. Karim, et al.
Science (2024) Vol. 386, Iss. 6717
Closed Access | Times Cited: 8
Proteomic approaches advancing targeted protein degradation
Gajanan Sathe, Gopal P. Sapkota
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 786-801
Open Access | Times Cited: 21
Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures
Marta Sanz Murillo, Amalia Villagran Suarez, Verena Dederer, et al.
Science Advances (2023) Vol. 9, Iss. 48
Open Access | Times Cited: 19
Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)
Thomas Geiger, Michael Walz, Christian Meyners, et al.
Angewandte Chemie International Edition (2023) Vol. 63, Iss. 3
Open Access | Times Cited: 16
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 578-578
Open Access | Times Cited: 7
Molecular glues and induced proximity: An evolution of tools and discovery
Stephanie Anne Robinson, J Co, Steven M. Banik
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1089-1100
Closed Access | Times Cited: 7
LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting
Yulan Xiong, Jianzhong Yu
Trends in Molecular Medicine (2024) Vol. 30, Iss. 10, pp. 982-996
Closed Access | Times Cited: 7
Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing pathways in neurodegenerative disorders and cancer
Aastha Kaushik, Somya Parashar, Rashmi K. Ambasta, et al.
Ageing Research Reviews (2024) Vol. 96, pp. 102279-102279
Closed Access | Times Cited: 6
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Sandra Kuemper, Andrew G. Cairns, Kristian Birchall, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 6
Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery
Rocío Marisol Espinoza-Chávez, Alessandra Salerno, Anastasia Liuzzi, et al.
ACS Bio & Med Chem Au (2022) Vol. 3, Iss. 1, pp. 32-45
Open Access | Times Cited: 22
The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson’s Disease
Xu Tang, Shuaishuai Xing, Mingkang Ma, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2282-2307
Closed Access | Times Cited: 14
Biomarker-activated multifunctional lysosome-targeting chimeras mediated selective degradation of extracellular amyloid fibrils
Zhenqi Liu, Qingqing Deng, Geng Qin, et al.
Chem (2023) Vol. 9, Iss. 7, pp. 2016-2038
Open Access | Times Cited: 13
Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease
Makoto Naoi, Wakako Maruyama, Masayo Shamoto‐Nagai, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 6, pp. 639-661
Closed Access | Times Cited: 5
Application of PROTACs in target identification and validation
Yang Liu, Jing Liang, Rui Zhu, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 5
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs
Donglu Zhang, Bin Ma, Peter S. Dragovich, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 5
Discovery of First-in-Class BAZ2A/B and BAZ2B-Selective Degraders
Leonardo Palaferri, Iván Cheng‐Sánchez, Katherine Gosselé, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 2, pp. 234-240
Closed Access
A patent review of von Hippel-Lindau (vhl)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present)
Aina Urbina, Alex J. Hallatt, Jack Robertson, et al.
Expert Opinion on Therapeutic Patents (2025), pp. 1-42
Closed Access
Advancements in PROTAC-based therapies for neurodegenerative diseases
Deyuan Kong, Liying Meng, Pengfei Lin, et al.
Future Medicinal Chemistry (2025), pp. 1-15
Closed Access
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders
Giulia Apprato, Giulia Caron, Gauri Deshmukh, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access
Application of DELs for E3 Ligase Ligand Discovery and Targeted Protein Degradation
Marie L. Malone, Nicholas A. Sanchez, Shimin Hu, et al.
Royal Society of Chemistry eBooks (2025), pp. 134-156
Closed Access

Scroll to top